After elucidating the roles of these checkpoint molecules in tumor immune escape, therapeutic mAbs were developed to disrupt interactions between PD-1/CTLA-4 and their respective ligands on tumor and immune cells [20,57]. This evidence concerns the gene CTLA4 and neoplasm.